Review Article
New Pathogenic Concepts and Therapeutic Approaches to Oxidative Stress in Chronic Kidney Disease
Table 2
Long term effects of SGLT2 inhibitors as approved glucose-lowering agents.
| Inhibitor | Diabetes | Effects | References |
| Canagliflozin | Type 2 | Reduces GFR, , BW, BP, FPG. | [266, 267] | Dapagliflozin | Type 2 | Reduces GFR, BP, BW, , albumin and stabilizes insulin dosing. | [268–272] | Empagliflozin | Type 1 Type 2 | Reduces GFR, plasma NO, , arterial stiffness, heart failure hospitalization, cardiovascular death. | [207, 273–275] | Ipragliflozin | Type 2 | Reduces , BW, FPG and improves liver function and lipid profile. | [276–278] |
|
|
Glycated haemoglobin, , glomerular filtration rate, GFR, fasting plasma glucose, FPG, body weight, BW, blood pressure, BP, and nitric oxide, NO.
|